CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016

SAN FRANCISCO, Dec. 10, 2015 (GLOBE NEWSWIRE) -- CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced that its Chief Medical Officer, George Lundberg, MD, will chair this year's Personalized Medicine World Conference, Silicon Valley session titled, "The Role of Practicing Pathologists in Personalized Medicine."

The January 25, 2016 track two session will start at 10:30 a.m. Pacific time. Panel participants include Steve Miller, PhD, Director of the Clinical Microbiology Laboratory at University California San Francisco, Kojo Elenitoba-Johnson, MD, Professor at the University of Pennsylvania's Perelman School of Medicine and Alexander Judkins, MD, PhD, Head of Pathology and Laboratory Medicine at Children's Hospital, Los Angeles.

In addition to his work at CollabRx, Dr. Lundberg is also Editor-at-Large for Medscape and a consulting professor at Stanford University. A frequent lecturer and radio and television guest, and a member of the National Academy of Medicine, the Industry Standard dubbed Dr. Lundberg "Online Healthcare's Medicine Man" in 2000 and from 1982-1999 he was Editor in Chief of JAMA (The Journal of the American Medical Association).

"George's years as a practicing physician and experience working with pathologists in today's personalized medicine-driven world will make him a great panel moderator," said Thomas Mika, CollabRx CEO. "His current role at CollabRx where he helps deliver expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes coupled with insights from Dr. Judkins, Dr. Miller and Dr. Elenitoba-Johnson will comprise a highly informational session."

The Personalized Medicine World Conference (PMWC) is an independent conference that brings together experts across healthcare and biotechnology sectors to help further the adoption of personalized medicine in the clinic.This year's Silicon Valley conference will be held January 24^th through the 27^st at the Computer History Museum in Mountain View, California.

About CollabRx, Inc.

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

About Rennova Health, Inc.

Rennova Health (Nasdaq:RNVA) owns and operates five diagnostics laboratories across the United States that provide clinical testing services specializing in toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. It offers its customers a complete, turnkey software product including: a proprietary laboratory ordering and reporting application, an advanced laboratory information management system, electronic health records, and an industry-leading platform for interpreting and reporting complex test results to physicians. Rennova's software is differentiated from that of its competitors by the breadth of its services, each of which is branded separately and is made available to physician groups in whole or in part. The software permits efficient and easy ordering and reporting, electronic health records integration, medical billing services and compliance, and diagnostic interpretation. For more information see www.rennovahealth.com.

CONTACT: Media Contact:
         Marla Kertzman for CollabRx
         408 482 3546
         [email protected]
         
         Rennova Health Company Contact:
         Tiffany VanDeMark
         Director of Marketing
         561 666 9821
         [email protected]